Coherus Biosciences (CHRS) Rating Increased to Sell at ValuEngine

Coherus Biosciences (NASDAQ:CHRS) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Wednesday.

A number of other analysts have also recently weighed in on CHRS. Maxim Group reissued a “buy” rating and issued a $20.00 target price (down previously from $40.00) on shares of Coherus Biosciences in a research note on Friday, September 8th. Cowen reiterated an “outperform” rating and set a $45.00 target price on shares of Coherus Biosciences in a research report on Friday, September 8th. Zacks Investment Research lowered shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. Credit Suisse Group reiterated an “outperform” rating and set a $17.00 target price (down from $24.00) on shares of Coherus Biosciences in a research report on Wednesday, September 27th. Finally, Citigroup restated a “buy” rating and issued a $23.00 price objective on shares of Coherus Biosciences in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $29.67.

Shares of Coherus Biosciences (NASDAQ:CHRS) traded up $1.85 on Wednesday, hitting $11.40. 1,476,385 shares of the stock were exchanged, compared to its average volume of 1,076,100. The firm has a market capitalization of $660.58, a price-to-earnings ratio of -2.10 and a beta of 3.89. The company has a debt-to-equity ratio of 1.84, a current ratio of 5.46 and a quick ratio of 5.46. Coherus Biosciences has a 1-year low of $8.05 and a 1-year high of $29.59.

Coherus Biosciences (NASDAQ:CHRS) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.26). Coherus Biosciences had a negative net margin of 73.89% and a negative return on equity of 582.31%. equities research analysts predict that Coherus Biosciences will post -4.39 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its position in shares of Coherus Biosciences by 32.7% in the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,785 shares during the period. Legal & General Group Plc grew its position in shares of Coherus Biosciences by 12.6% in the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 1,046 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Coherus Biosciences by 497.4% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,600 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 10,491 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Coherus Biosciences during the 2nd quarter worth about $185,000. Finally, Voya Investment Management LLC lifted its stake in shares of Coherus Biosciences by 32.2% during the 2nd quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock worth $253,000 after buying an additional 4,293 shares during the last quarter. 81.00% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Coherus Biosciences (CHRS) Rating Increased to Sell at ValuEngine” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/03/coherus-biosciences-chrs-rating-increased-to-sell-at-valuengine.html.

About Coherus Biosciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply